Enterprise Europe Network

A range of novel hybridoma, monoclonal and polyclonal antibodies available for licencing

Country of origin:
Country: 
UNITED KINGDOM
Opportunity:
External Id: 
TOUK20201216002
Published
06/01/2021
Last update
19/01/2021
Expiration date
20/01/2022

Keywords

Partner keyword: 
Cytology, Cancerology, Oncology
Medical Research
Pharmaceutical Products / Drugs
Protein Engineering
In vitro Testing, Trials
Monoclonal Antibodies and Hybridomas
Cellular and Molecular Biology
Oncology
Anatomy, Pathology, Immunology, Physiology
Research and experimental development on biotechnology
Other professional, scientific and technical activities n.e.c.
Other human health activities
EXPRESS YOUR INTEREST

Summary

Summary: 
A UK non-profit organisation can source and supply a range of antibodies, relating to a variety of life science research areas including, but not limited to, oncology, immunology, and neurobiology. The antibodies are available to life science tool providers and researchers in biotech, pharma and academic institutes via licensing agreement.

Description

Description: 

A UK non-profit organisation can source and supply a range of antibodies, to life science tool providers and researchers in biotech, pharma and academic institutes.

They have access to a range of novel hybridoma, monoclonal and polyclonal antibodies, from over 150 institutes worldwide, relating to a variety of life science research areas including oncology, immunology, neurobiology, and cell-type or organelle markers.

The diverse and comprehensive portfolio allows researchers to source antibodies ideally suited to their needs. Life science tool providers can access these antibodies via an exclusive or non-exclusive licensing agreement to expand their commercial portfolios.

Advantages & innovations

Cooperation plus value: 
Over 2700 hybridoma, monoclonal, and polyclonal antibodies available in the portfolio, with new antibodies added weekly providing valuable revenue to researchers who have invented the antibodies. Some of the most popular antibodies include: Anti-CD3 (cluster of differentiation) [UCH-T1], Anti-CD45RO [UCH-L1], Anti-Integrin aM [ICRF44], Anti-FCGR1 (Fc gamma receptors) [10.1], Anti-PTPRC [HLe-1(2D1)], Anti-cMyc [9E10], Anti-PECAM1 [JC70], brainbow polyclonal antibodies and Anti-G quadruplex recombinant [BG4].

Stage of development

Cooperation stage dev stage: 
Already on the market

Partner sought

Cooperation area: 
Type: Industry or academia Activity of partner: Life science researchers Specific role of partner sought: The licensing of antibodies for use in their research.

Type and size

Cooperation task: 
SME 11-50,University,R&D Institution,SME <10,>500 MNE,251-500,SME 51-250,>500